Strategic Advancements in Interventional Radiology: A Systematic Literature Review of Emulsion Dynamics in cTACE and NBCA Glue Embolization in 2026

Introduction

The discipline of interventional radiology (IR) has solidified its position at the center of precision oncology and vascular medicine. As of 2026, the management of hypervascular tumors, particularly hepatocellular carcinoma (HCC), and complex vascular anomalies like arteriovenous malformations (AVMs) is governed by sophisticated liquid embolic protocols. Central to these procedures is the physicochemical stability of emulsions—specifically ethiodized oil (Lipiodol)-drug mixtures in conventional transarterial chemoembolization (cTACE) and N-butyl cyanoacrylate (NBCA) glue mixtures in vascular obliteration.

Despite the clinical success of these modalities, procedural outcomes are strictly dictated by the structural integrity of delivery systems and the stability of the embolic mixtures. This review examines the current state of emulsion science, the definitive 2026 society guidelines supporting conventional techniques, and the critical role of standardized mixing systems like SATMix in overcoming material degradation and economic barriers.

Foundational Principles and Emulsion Science in cTACE

The efficacy of cTACE is intrinsically linked to the behavior of ethiodized oil, which serves as a drug vehicle, a transient embolic agent, and a radiopaque marker. The successful administration of cTACE requires the creation of a stable emulsion between the oily Lipiodol and an aqueous chemotherapy solution (e.g., doxorubicin, epirubicin, or miriplatin).

Physicochemical Characteristics and Stability Determinants

The stability of a Lipiodol-drug emulsion determines drug delivery efficiency and systemic toxicity. Clinically, water-in-oil (w/o) emulsions are superior to oil-in-water (o/w) configurations because the continuous oily phase “shields” the drug, ensuring it is carried directly into the tumor interstitium and sequestered there.

Key variables dictating stability include:

• Aqueous-to-Lipid Phase Ratio: Research indicates that a higher Lipiodol content significantly enhances stability. Emulsions with a 1:4 aqueous-to-lipid ratio can remain stable for more than 72 hours, while a 1:1 ratio often results in phase separation within 15 minutes.

• Aqueous Phase Composition: The addition of non-ionic contrast agents, such as iohexol (Omnipaque), improves stability by increasing drug solubility (exceeding 69 mg/mL) and modifying the viscosity of the aqueous phase.

• Mechanical Energy: Standard 2026 protocols require a minimum of 20 vigorous back-and-forth pumping exchanges through a 3-way or 4-way stopcock to achieve optimal droplet sizes between 70 and 100 mum.

The Drop Test: A Bedside Standard for Quality Control

The “drop test” remains the mandatory qualitative assessment in 2026 for verifying emulsion type. A single droplet of the emulsion is placed into a container of saline. In a true w/o emulsion, the droplet maintains its shape and sinks or floats without dispersing. If the droplet dissolves or creates a cloudy solution, it indicates an o/w mixture, which is unsuitable for administration as it leads to rapid systemic drug efflux.

 

2026 Society Guidelines: cTACE and Glue Embolization

The year 2026 has seen a harmonized effort by major societies to standardize interventional protocols, focusing on superselectivity and material safety.

EASL and BCLC 2026 Updates for HCC

The European Association for the Study of the Liver (EASL) and the Barcelona Clínic Liver Cancer (BCLC) group updated their guidelines in 2025/2026, presented at the Liver Cancer Summit in Paris.

• Multiparametric Decision-Making: Guidelines now incorporate a multiparametric model, personalizing treatment based on tumor burden, liver function, and patient performance status.

• Radical TACE Strategy: Superselective cTACE (ss-cTACE) is recommended for tumors smaller than 5 cm involving a maximum of two segments.

• “On-Demand” Treatment: Experts recommend a minimum of two sequential cTACE procedures in a treatment cycle, with an “on-demand” approach (up to 3-4 times per year) based on tumor response.

CIRSE 2026 Standards of Practice

The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) released several landmark documents in 2026:

• Endovascular Treatment of Acute Pulmonary Embolism: New standards led by A. Basile emphasize early intervention and the rise of PE response teams.

• Material Standardization: CIRSE emphasizes the use of Lipiodol-resistant polymers for stopcocks and syringes to prevent device failure and air embolism during high-pressure injections.

SIR 2026 Clinical Practice Guidance

The Society of Interventional Radiology (SIR) 2026 Annual Meeting in Toronto introduced new practice guidance for chronic conditions:

• Chronic Pelvic Pain: SIR published evidence-based guidance for the treatment of venous-origin chronic pelvic pain (VO-CPP), highlighting the role of liquid embolic agents like NBCA in permanent venous occlusion.

• Radial Access Protocols: 2026 guidelines favor radial access for many embolization procedures to improve patient comfort and reduce access-site complications.

Clinical Comparative Efficacy: Conventional vs. Modern Alternatives

The Ono et al. Paradigm and TE4 Response Rates

High-ranking research, particularly the JIVROSG-1302 PRESIDENT study and analyses by Ono et al., has challenged the superiority of drug-eluting beads (DEB-TACE) in specific cohorts.

• Small Tumors (< 3 cm): cTACE achieves significantly higher complete response (CR) and TE4 rates (treatment effect equivalent to CR) than DEB-TACE.

• Fluid Dynamics: Unlike microspheres (restricted to 100 to 500mum), Lipiodol emulsions penetrate the peritumoral portal venules and microvascular “sump,” ensuring total tumor coverage.

Endpoint (Tumors < 3 cm)	cTACE (Emulsion)	DEB-TACE (Beads)	Significance
CR at 1 Month	84.2%	35.7%	p < 0.001
CR at 3 Months	75.2%	27.6%	p < 0.001
TE4 Response Rate	74.4%	51.0%	p < 0.001

Balloon-Occluded TACE (B-TACE)

B-TACE utilizes a microballoon to modify local hemodynamics, reducing the balloon-occluded arterial stump pressure (BOASP) below 64 mm/Hg. This pressure gradient facilitates the forceful infusion of the Lipiodol emulsion into the tumor and prevents proximal backflow, further improving TE4 rates in intermediate lesions (30 to 50 mm).

Glue Embolization: NBCA-Lipiodol Dynamics

NBCA is a permanent liquid embolic agent that polymerizes instantly upon contact with ionic substances (anions in blood).

Polymerization and Mixing Protocols

Pure NBCA cures in 0.087 seconds, requiring dilution with Lipiodol to slow the polymerization rate and provide visibility.

• Mixing Order: Recent studies suggest that mixing Lipiodol with contrast first, and then adding NBCA, produces the most uniform particle sizes (1.6–3.3 mum) and reduces catheter adhesiveness.

• The Sandwich Technique: Microcatheters must be flushed with 5% dextrose (D5), a non-ionic solution, to prevent premature polymerization inside the catheter.

NBCA:Lipiodol Ratio	Curing Time (In Vitro)	Clinical Application
1:1 (50% NBCA)	3.2 Seconds	Proximal occlusion, High-flow fistula
1:2 (33% NBCA)	4.7 Seconds	Standard AVM nidus
1:3 (25% NBCA)	7.5 Seconds	Distal nidal penetration
1:4 to 1:8	> 10 Seconds	Very low-flow / large nidal beds

Arteriovenous Malformations (AVMs)

Liquid embolic agents are essential for AVM management as they can flow through the dysplastic microvascular “nidus.” Mechanical agents like coils often lead to recurrence by only occluding feeder vessels. Technical success rates for NBCA in AVMs are reported between 96.4% and 100%, with clinical success for symptom relief reaching 91%.

The Polycarbonate Vulnerability: Material Science in 2026

Lipiodol is chemically aggressive toward polycarbonate (PC), the standard plastic for medical stopcocks.

Mechanism of Environmental Stress Cracking (ESC)

Lipiodol penetrates the PC polymer matrix, reducing intermolecular forces and allowing micro-cracks to form under mechanical stress (e.g., luer-lock tightening). This leads to:

1. Staff Safety Risks: Catastrophic device failure can spray chemotherapy or glue onto the clinical team.

2. Patient Safety Risks: Cracks introduce air into the system, increasing the risk of air embolism.

3. Chemical Contamination: Released plasticizers and polymers enter the patient’s vasculature.

Research shows PC stopcocks can fail within 15-60 minutes of contact. Specialized Lipiodol-resistant polymers (polypropylene, polyamide, HDPE) are now mandatory for these procedures.

SATMix: Disrupting the IR Monopoly through Standardization

Historically, the interventional market has been dominated by high-cost “premium” mixing kits, often inaccessible to budget-constrained hospitals. The SATMix system by SATMED Health was designed to address these gaps.

Technical Architecture and Procedural Advantages

SATMix is a high-performance, single-use mixing kit designed for optimal price-to-performance.

• Lipiodol-Resistant Polymer: Validated for 24-hour resistance, preventing device failure and chemical leaching.

• 3-Way 4-Port Stopcock: A unique “continuous-flow” design allows clinicians to mix, remix, and refill without ever disconnecting from the microcatheter, minimizing air embolism and contamination risks.

• Standardized Protocol: Engineering ensures stable w/o emulsions through a standardized 20-exchange mixing protocol, removing manual variability.

• Ergonomic Precision: Includes 1 mL and 3 mL syringes with rotary finger grips for high-pressure tactile feedback in small vessels.

Economic Impact and Global Democratization

SATMix disrupts the pricing monopoly of traditional medical giants by offering a 66% cost reduction via a streamlined supply chain.

• Affordable Standardization: The lower price point allows high-volume centers to standardize ss-cTACE and glue protocols across all patients, rather than reserving high-quality kits only for “high-risk” cases.

• Extended Shelf Life: A 5-year expiry date further reduces waste and procurement overhead.

Future Applications and Evolving Horizons

Portal Vein Embolization (PVE) and Liver Regeneration

NBCA-Lipiodol mixtures are increasingly used in PVE to induce hypertrophy in the future liver remnant (FLR) before major resection. Glue achieves a more distal and permanent occlusion than particulate agents, stimulating faster liver growth.

AI and Deep Learning in IR

Deep learning frameworks now integrate MRI texture features and clinical data to predict early TACE efficacy with an AUC of up to 0.98. AI-powered automated tumor feeder detection (AFD) is also used during CBCT to guide superselective catheterization.

Theranostics and Nanomedicine

Lipiodol emulsions serve as carriers for gold nanorods and other nanoparticles in site-directed photothermal therapy (PTT). Stable emulsions are critical to prevent off-target toxicity in these next-generation applications.

Histotripsy

The 2026 landscape includes histotripsy—a non-invasive, non-thermal ultrasound technology that mechanically disintegrates tumor tissue while sparing blood vessels. This may complement emulsion-based therapies in multidisciplinary oncology.

Strategic Conclusions

The literature and 2026 society guidelines confirm that the clinical success of cTACE and glue embolization is a function of material science and standardized delivery. Superselective cTACE remains the gold standard for small-to-intermediate HCC local control. NBCA glue is the definitive agent for permanent AVM obliteration and emergency hemostasis.

The introduction of SATMix represents a pivotal shift toward a safer, reproducible, and economically sustainable model of interventional care. By providing Lipiodol-resistant, closed-system kits at a fraction of the cost, SATMix enables the global standardization of these life-saving procedures, ensuring that high-performance technology is accessible to every IR suite worldwide.

Reference List

1. Patidar, Y., Khisti, R., Yadav, A., Mukund, A., & Sarin, S. K. (2019). Outcome of conventional transarterial chemoembolization (cTACE) for ruptured hepatocellular carcinoma. Hepatology International, 13, 663–669. https://pmc.ncbi.nlm.nih.gov/articles/PMC6639859/

2. Loffroy, R., Guiu, B., Cercueil, J. P., & Krausé, D. (2009). Endovascular therapeutic embolisation: an overview of occluding agents and their effects on embolised tissues. Current Vascular Pharmacology, 7(2), 250-263. https://pmc.ncbi.nlm.nih.gov/articles/PMC8509239/

3. Yakes, W. F., et al. (1990). Clinical applications of endovascular techniques in the management of vascular malformations. Cardiovascular and Interventional Radiology, 13(4), 211-220. https://pmc.ncbi.nlm.nih.gov/articles/PMC4862843/

4. SATMED Health. (2024). SatMix: World’s First High Performance Single Use Patient Mixing Kit. SATMED Health Research Division.

5. de Baere, T., et al. (2016). Physicochemical stability and drug release of doxorubicin-lipiodol emulsions for transarterial chemoembolization. Journal of Vascular and Interventional Radiology, 27(1), 85-93. https://www.researchgate.net/publication/334434463

6. Lucatelli, P., et al. (2022). Superselective conventional TransArterial ChemoEmbolization (ss-cTACE): An expert consensus. La Radiologia Medica, 127(9), 1011-1025. https://ouci.dntb.gov.ua/en/works/lxZdgmQ7/

7. Idée, J. M., et al. (2014). Lipiodol as a drug-delivery system for transarterial chemoembolisation of hepatocellular carcinoma: A review. Critical Reviews in Oncology/Hematology, 92(3), 135-147. https://doi.org/10.1016/j.critrevonc.2014.07.001

8. Guerbet. (2021). Interventional Imaging: Results Presentation H1 2021. https://www.guerbet.com/sites/default/files/2025-07/guerbet-23-09-2021-h1-2021-results-presentation_vdef.pdf

9. Ono, Y., et al. (2021). Comparison of local efficacy between drug-eluting bead TACE and conventional TACE for hepatocellular carcinoma. CardioVascular and Interventional Radiology, 44, 1550-1558. https://www.researchgate.net/publication/341633625

10. Lencioni, R., et al. (2016). Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety. Hepatology, 64(1), 106-116. https://pmc.ncbi.nlm.nih.gov/articles/PMC11864999/

11. Ikeda, M., et al. (2020). JIVROSG-1302: A randomized phase II study of conventional TACE versus drug-eluting bead TACE (PRESIDENT study). ASCO Annual Meeting, Abstract 4518. https://www.researchgate.net/publication/341633625

12. Lee, I. J., et al. (2023). 2022 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) Korea practice guidelines for hepatocellular carcinoma. Journal of Liver Cancer, 23(1), 1-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC9830139/

13. Matsumoto, T., et al. (2022). Balloon-occluded transarterial chemoembolization (B-TACE) for hepatocellular carcinoma: Hemodynamic changes and clinical results. Translational Gastroenterology and Hepatology, 7, 13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11292099/

14. Wang, X., et al. (2025). Deep learning combines MRI texture and clinical factors to predict early efficacy in TACE. Oncologie, 27(1), 54-62. https://www.researchgate.net/publication/398624842

15. Comby, P. O., et al. (2021). Endovascular use of cyanoacrylate-lipiodol mixture for peripheral embolization. Journal of Clinical Medicine, 10(19), 4320. https://pmc.ncbi.nlm.nih.gov/articles/PMC8509239/

16. Tong, Y. C., et al. (2025). Percutaneous NBCA glue embolization combined with arterial embolization for extracranial AVMs. Journal of Clinical Imaging Science, 15(1), 19. https://clinicalimagingscience.org/percutaneous-n-butyl-cyanoacrylate-glue-embolization-combined-with-arterial-embolization-for-extracranial-arteriovenous-malformations/

17. Basile, A., et al. (2026). CIRSE Standards of Practice on Endovascular Treatment of Acute Pulmonary Embolism. Cardiovascular and Interventional Radiology. https://www.cirse.org/publications/standards-of-practice/cirse-documents/

18. Lookstein, R. A., et al. (2026). Society of Interventional Radiology practice guidance for treatment of chronic pelvic pain. Journal of Vascular and Interventional Radiology. https://www.sirweb.org/for-press/society-of-interventional-radiology-publishes-practice-guidance-for-treatment-of-chronic-pelvic-pain/

19. Reig, M., et al. (2025). Updated European guidelines (EASL) for the management of hepatocellular carcinoma. Journal of Hepatology. https://www.clinicbarcelona.org/en/news/new-european-guidelines-to-improve-the-treatment-of-hepatocellular-carcinoma

20. Kidani, N., & Hirotsune, N. (2024). NBCA Basic Knowledge: Rules of use and potential pitfalls. Japanese Journal of Radiology. https://pmc.ncbi.nlm.nih.gov/articles/PMC11864999/